Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Income from Continuing Operations: 2012-2025

Historic Income from Continuing Operations for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$18.6 million.

  • Enanta Pharmaceuticals' Income from Continuing Operations rose 35.08% to -$18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.8 million, marking a year-over-year increase of 29.41%. This contributed to the annual value of -$81.8 million for FY2025, which is 29.41% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Income from Continuing Operations of -$18.6 million as of Q3 2025, which was down 1.82% from -$18.3 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Income from Continuing Operations high stood at -$18.3 million for Q2 2025, and its period low was -$39.1 million during Q2 2023.
  • For the 3-year period, Enanta Pharmaceuticals' Income from Continuing Operations averaged around -$27.5 million, with its median value being -$28.1 million (2023).
  • Per our database at Business Quant, Enanta Pharmaceuticals' Income from Continuing Operations slumped by 503.91% in 2021 and then soared by 42.00% in 2024.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Income from Continuing Operations stood at -$30.1 million in 2021, then rose by 3.75% to -$29.0 million in 2022, then dropped by 15.25% to -$33.4 million in 2023, then spiked by 33.28% to -$22.3 million in 2024, then surged by 35.08% to -$18.6 million in 2025.
  • Its Income from Continuing Operations was -$18.6 million in Q3 2025, compared to -$18.3 million in Q2 2025 and -$22.6 million in Q1 2025.